|Pawe³ Górski, Cezary Pa³czyński, Jolanta Walusiak|
Klinika Chorób Zawodowych Instytutu Medycyny Pracy w £odzi, ul. ¶w. Teresy 8, 90-950 £ód¼
Once-daily mometasone furoate nasal spray is a new intranasal glucocorticoid for the treatment of allergic rhinitis. The aim of the study was to evaluate the effectiveness and tolerability of mometasone furoate aqueous nasal spray in comparison to placebo vehicle, in patients with perennial allergic rhinitis. This was a randomised, double - blind, placebo - controlled parallel group study in 105 patients at 5 centres in Poland. Patients allergic to at least one perennial allergen, confirmed by medical history, skin prick test results or presence of allergen - specific IgE in the serum and adequate symptoms were eligible to receive for 8 weeks mometasone furoate, 200µg once daily or placebo vehicle control. Physician evaluation of symptoms was performed after 1, 4 and 8 weeks of treatment and the patients kept daily (morning) symptom diaries. 89 patients were valid for efficacy. Mometasone furoate was significantly (p=0.05) more effective than placebo and well tolerated. Active treated patients demonstrated significant improvement at 1 week of therapy (p<0.005). The results of the study indicate that mometasone furoate aqueous nasal spray adequately controls of perennial allergic rhinitis, offers the advantage of once daily treatment, and is well tolerated.
pages: from 223 to 228
|estimated time of download (167 kB)|